Objective To explore the application value of empagliflozin and ticagrelor in patients with diabetic angina pectoris.Methods Clinical data of 100 patients with diabetic angina treated in Quanzhou First Hospital from October 2022 to October 2023 were retrospectively selected and were divided into control group(n=50)and study group(n=50)according to different treatment methods.The control group was treated with metformin combined with ticagrelor,and the study group was treated with engaglizin combined with ticagrelor.Before intervention and 2 months after interven-tion,fasting blood glucose levels and 2 h postprandial blood glucose levels were compared between the two groups,and the incidence of adverse reactions such as dizziness,allergy,nausea and vomiting were compared between the two groups.Results After the intervention,the fasting blood glucose level of the study group was(5.53±0.56)mmol/L,and the 2-hour postprandial blood glucose level was(6.89±0.23)mmol/L,both lower than those of the control group,and the differences were statistically significant(t=3.896,14.452,both P<0.001).There was no significant difference in the incidence of adverse reactions between the two groups(2.00%vs 4.00%)(χ2=0.344,P>0.05).Conclusion In pa-tients with angina pectoris diabetes,the combination of empagliflozin and ticagrelor can reduce blood glucose levels without increasing the adverse reactions,and has a high safety.
EmpagliflozinTicagrelorDiabetes mellitusAngina pectorisRemission of symptomsBlood glucose level
NETL
NSTL
万方数据
